---
category: corporate-action
circular_id: efaa01408457fd2a
date: '2026-01-21'
description: Titan Biotech Ltd announces sub-division of equity shares from Rs.10/-
  each into five equity shares of Rs.2/- each, with record date of February 20, 2026.
draft: false
guid: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={6633B340-6395-465E-AF49-87AFFC0BDC14}&noticeno=20260121-38&dt=01/21/2026&icount=38&totcount=58&flag=0
impact: medium
impact_ranking: medium
importance_ranking: medium
justification: Stock sub-division affects share price and liquidity but is a routine
  corporate action. Impacts all shareholders of Titan Biotech with ISIN changes requiring
  tracking.
pdf_url: https://www.bseindia.com/markets/MarketInfo/DownloadAttach.aspx?id=20260121-38&attachedId=
processing:
  attempts: 1
  content_hash: bc4c2d2640720429
  processed_at: '2026-01-21T19:01:49.775043'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2026-01-21T13:15:01+00:00'
rss_url: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={6633B340-6395-465E-AF49-87AFFC0BDC14}&noticeno=20260121-38&dt=01/21/2026&icount=38&totcount=58&flag=0
severity: medium
source: bse
stocks:
- TITANBIOTECH
tags:
- corporate-action
- sub-division
- stock-split
- equity-shares
- titan-biotech
- record-date
- isin-change
title: 'Sub-Division of Equity Shares of Titan Biotech Ltd (Scrip Code: 524717)'
---

## Summary

BSE has notified that Titan Biotech Ltd (Scrip Code: 524717) will undergo a sub-division of its equity shares. Each existing equity share with a face value of Rs.10/- will be split into five equity shares with a face value of Rs.2/- each. The record date for this corporate action is February 20, 2026, and the new share structure will be effective from the same date.

## Key Points

- Company: Titan Biotech Ltd (Scrip Code: 524717)
- Corporate Action: Sub-division of equity shares
- Sub-division Ratio: 1:5 (One share of Rs.10/- into five shares of Rs.2/-)
- Record Date: February 20, 2026
- Effective Date: February 20, 2026
- Old ISIN (INE150C01011) for Rs.10/- shares will become invalid for exchange transactions from February 20, 2026
- New ISIN for Rs.2/- shares will be communicated via separate notice
- Notice Reference: DR-825/2025-2026
- Issued by: Marian Dsouza, Assistant Vice President â€“ Listing Compliance & Operations

## Regulatory Changes

No regulatory framework changes. This is a standard corporate action permitted under existing regulations where a company subdivides its shares to improve liquidity and affordability.

## Compliance Requirements

- Trading members must note the record date of February 20, 2026
- The existing ISIN No. INE150C01011 (Rs.10/- paid-up) will not be valid for transactions on or after February 20, 2026
- Market participants must update their systems to reflect the new ISIN once notified
- Demat accounts will be automatically credited with subdivided shares
- All references to share capital and shareholding must be adjusted to reflect the 1:5 split

## Important Dates

- **January 21, 2026**: Notice issued by BSE
- **February 20, 2026**: Record date for sub-division
- **February 20, 2026**: Effective date - new Rs.2/- shares become valid for trading
- **February 20, 2026**: Old ISIN (INE150C01011) becomes invalid for exchange transactions

## Impact Assessment

**Market Impact**: The sub-division will reduce the per-share price of Titan Biotech to one-fifth of the current price, potentially improving liquidity and making shares more accessible to retail investors. Outstanding shares will increase five-fold while market capitalization remains unchanged.

**Operational Impact**: Shareholders will automatically receive four additional shares for every one share held as of the record date. This affects portfolio accounting, holding statements, and all share-related calculations. The ISIN change requires system updates across depositories, trading platforms, and custodian systems.

**Investor Impact**: Existing shareholders face no dilution - their proportionate ownership remains unchanged. However, they must track the ISIN change and verify correct credit of subdivided shares in their demat accounts post-record date.